Participated · Series A · Oct 2025

Founded in 2016, Exeliom Biosciences engineers live-bacterial, NOD2-targeting immunomodulators to boost patients’ innate immune responses. Its lead candidate, EXL01, is a Faecalibacterium prausnitzii-derived therapy that reprograms macrophages and the tumour micro-environment to overcome resistance to existing treatments. EXL01 is currently being tested in three Phase 2 oncology trials alongside immune-checkpoint inhibitors, including what the company calls the largest randomised Phase 2 study worldwide of a bacterial therapy in gastric cancer. The programme also includes a Phase 2 trial in Crohn’s disease and a study aimed at preventing recurrent Clostridioides difficile infection. Fresh capital will fund proof-of-concept Phase 2 work, preparation for a new U.S. cancer indication and broader international expansion. To date, Exeliom has secured nearly €30 million in combined dilutive and non-dilutive financing, underscoring strong investor confidence in its precision immunotherapy platform.

Led · Equity · Apr 2025

Okeiro, formerly Predict4Health and based in Paris, builds an advanced clinical decision support platform that leverages AI to prevent organ failure across kidney, lung, heart and liver transplants and advanced chronic diseases. At the core of the platform is the iBox algorithm, a clinically validated predictive model developed with APHP and INSERM that is marked as a medical device and qualified as a surrogate endpoint by the FDA and EMA. The technology enables physicians to identify post-transplant complications, improve patient monitoring and treatment protocols, and accelerate clinical trial timelines. The platform is already implemented in transplant centers across France, is benefiting thousands of patients, and has achieved national reimbursement through the French National Health Insurance. Okeiro is currently running a randomized clinical trial across 16 hospital centers in six countries (France, Germany, the United Kingdom, Austria, Israel and Spain) to compare outcomes for physicians using the platform versus standard care; interim results are very positive and the study will complete in a few months. The company plans to use the newly raised funds to accelerate deployment in France and internationally and to develop new AI tools to further improve diagnostics, therapeutic recommendations, and clinical research in end-stage chronic disease and transplant patients.

Led · Equity · Jun 2024

GPN Vaccines is developing a vaccine against one of the world’s most prolific bacterial pathogens, responsible for a wide range of illnesses including middle ear infections and severe pneumonia. The company is described as an Australian start-up. In its latest financing the business secured capital that has produced a reported $300 million valuation. The round raised US$12 million (reported as A$18 million). The financing was led by New York‑based Forepont Capital, San Francisco’s Kern Capital and Mike Gregg, founding partner of local fund Shearwater Capital. The article does not report revenue, users, founding year, or additional operational metrics. GPN Vaccines is developing Gamma-PN (also referred to as Gamma-PNTM), a candidate broad-spectrum pneumococcal vaccine intended to protect against all S. pneumoniae serotypes. The company has commenced a first-in-human clinical trial in 50–69-year-old volunteers in Australia to evaluate the vaccine's ability to elicit protective, serotype-independent opsonophagocytic antibody responses. Management says the program aims to offer protection against serotypes not covered by existing vaccines and that preclinical data were published in mBio. Financially, the company strengthened its balance sheet with the recently closed Series A3 round and received a grant from the South Australian Government’s Research and Innovation Fund. GPN Vaccines is a public (unlisted) company and says the new funding extends its runway and resources to comprehensively test Gamma-PNTM in human trials. The team emphasizes the global importance of a vaccine that could protect against emerging pneumococcal serotypes.

Led · Series A · Dec 2023

BCV develops an actuable steerable mechatronic guidewire system controlled by a smart handle and generator, using shape‑memory alloy to enable distal tip control. The device is designed to enhance safety, reduce procedure time, and improve outcomes in stroke and arterial disease interventions. BCV completed a first in‑human clinical trial in 2022 at Rothschild Foundation Hospital in Paris and has filed a pre‑submission application with the FDA; the system remains an investigational device and is not commercially available. The company has built an in‑house manufacturing and R&D plant in Reims to support production and miniaturization. Founded in 2016, BCV developed its core mechatronic technology with ISIR at Sorbonne University and INSERM. The current funding is intended to accelerate development toward FDA and CE mark approvals and go‑to‑market efforts.

Led · Series B · Jan 2023

Precision Neuroscience is a New York City–based brain–computer interface (BCI) company led by CEO Michael Mager. The firm is developing what it describes as the only BCI that is minimally invasive, safely removable, and able to process large volumes of neural data. Its technology is aimed at delivering breakthrough treatments for millions of patients suffering from neurological illnesses by seamlessly interfacing with the brain. The design prioritizes patient safety and high-bandwidth data capture, distinguishing it from other implantable neurotech solutions. Newly secured funding will be used to expand operations and accelerate research and development efforts. The article did not disclose any revenue, user figures, or other operating metrics.